Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.050
+0.097 (10.19%)
Jun 6, 2025, 1:51 PM - Market open
Ocugen Employees
Ocugen had 95 employees as of December 31, 2024. The number of employees increased by 30 or 46.15% compared to the previous year.
Employees
95
Change (1Y)
30
Growth (1Y)
46.15%
Revenue / Employee
$47,600
Profits / Employee
-$605,316
Market Cap
306.63M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
OCGN News
- 1 day ago - Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - GlobeNewsWire
- 10 days ago - Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease - GlobeNewsWire
- 4 weeks ago - Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Ocugen Provides Business Update with First Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress - GlobeNewsWire
- 2 months ago - Ocugen to Present at the 2025 Cell & Gene Meeting on the Med - GlobeNewsWire
- 2 months ago - Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema - GlobeNewsWire